|
|
|
Serogroups B and C are predominant in Europe. The division has two businesses: Novartis Vaccines and Chiron.5 billion and net income of USD 8.] Novartis Vaccines and Diagnostics, Scientific Platform: Meningococcal Diseases, Revised December 11, 2008 [4.
Data to Be Presented at the 55th Annual Meeting of the Radiation Research Society in October
MISSION VIEJO, Calif.
In addition to the statistically significant (P< 0. The product also has an established stability profile that permits long-term storage.
Potential for AEOL 10150 as a Countermeasure Against Multiple Terrorist Threats
AEOL 10150 has shown significant protective effects against radiation and mustard gas in animal models. Important factors that could cause results to differ include risks associated with uncertainties of progress and timing of clinical trials, scientific research and product development activities, difficulties or delays in development, testing, obtaining regulatory approval, the need to obtain funding for pre-clinical and clinical trials and operations, the scope and validity of intellectual property protection for Aeolus' product candidates, proprietary technologies and their uses, and competition from other biopharmaceutical companies.
xanax effexor opoids generic xanax xr greenstone generic xanax hydrocodone and xanax with mastercard id xanax andnot sale xanax day delivery time xanax prison talk xanax to klonipin
"
About the Novartis Vaccines global meningococcal franchise
Menveo is based on the same proprietary technology Novartis Vaccines pioneered to produce Menjugate, a meningococcal serogroup C conjugate vaccine approved outside the US since 2000 for use in individuals from age 2 months through adulthood. The company has already distributed more than 26 million doses of Menjugate around the world and produced MenZB, a vaccine against a strain of meningococcus B specific to a recent outbreak in New Zealand. Distribution of serogroups varies widely from geographic region to region and changes over time. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. The six month study, led by Zeljko Vujaskovic, M.
“AEOL 10150 continues to demonstrate significant, protective effects when administered after exposure to radiation,” stated John L. Specifically, AEOL 10150 is able to down-regulate oxidative stress and severe inflammation, which is responsible for much of the tissue destruction that occurs as a result of radiation exposure.
AEOL 10150 offers several unique advantages as a countermeasure for the treatment of ARS, mustard gas and chlorine gas for civilian and military populations. This approach has the added benefit of not requiring biodosimetry (a means of laboratory analysis of the blood to determine the level of radiation exposure).
|
|
No News has been posted yet
|
|
|
Forgotten your password? Request a new one here.
|
 Guests Online: 1
No Members Online
Registered Members: 1
Unactivated Members: 0
Newest Member: Owen Electrical
|
|
v6.01.1 © 2003-2005